Silence Therapeutics
SLN | NASDAQ
$19.80
-$0.03 (-0.15%)
At close: Nov 16, 2026, 4:00 PM ET
$19.72
-$0.08 (-0.42%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Silence Therapeutics Company Profile
Company profile explainedCompany Profile
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Key Executives
| Name | Position |
|---|---|
| Iain Gladstone Ross | Interim CEO & Chairman of the Board |
| Curtis Rambaran | Chief Medical Officer |
| Gabriel | Chief Technical Operations Officer |
| Gem Gokmen Hopkins | Head of IR & Corporation Communications |
| Jaimin Shah | SVP & General Counsel |
| Marie Wikstrom Lindholm | Chief Scientific Officer |
| Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director |
| Steven J. Romano | Executive Vice President and Chief Research & Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | DEFA14A | Filing |
| Oct 19, 2026 | DEFA14A | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | SC 13D/A | [Amend] Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4 | Filing |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 424B5 | Filing |
Silence Therapeutics
| Country | United Kingdom |
| IPO Date | Sep 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Iain Gladstone Ross |
Contact Details
72 Hammersmith Road London,
GL W6 7AP United Kingdom
Stock Details
| Ticker Symbol | SLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479615 |
| CUSIP Number | 82686Q101 |
| ISIN Number | US82686Q1013 |
| SIC Code | 2834 |
Recent News
- 4 days ago / businesswire.comSilence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
- 13 days ago / businesswire.comSilence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
- 28 days ago / gurufocus.comAre BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
- 28 days ago / zacks.comDoes Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
- 28 days ago / globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
- 29 days ago / proactiveinvestors.comSilence Therapeutics jumps 59% on Merck takeover
- 29 days ago / benzinga.comSilence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
- 29 days ago / businesswire.comSLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
- 29 days ago / wsj.comGermany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Add to Watchlist
Select watchlists to add or remove SLN